Directorate Update

RNS Number : 3757D

Venn Life Sciences Holdings PLC

25 June 2019

 

25 June 2019

Venn Life Sciences Holdings Plc

("Venn Life Sciences" or the "Company")

Directorate Update

The Board has made excellent progress in selecting a further independent non-executive director. An appointment is expected by the end of August 2019. Following further consideration of the Board composition, the Board has concluded that Brendan Buckley will no longer be considered an "independent director" with respect to the Company's application of the QCA Code. The Board reiterates its view that Brendan Buckley is of independent character and judgement and will play a key role in the development of Venn Life Sciences from his position as Chairman. Additionally, reference to "UK Corporate Governance Code" on page 23 of the Admission Document refers to the QCA Code.

The Board is committed to upholding the highest standards of corporate governance. Further detail of the Board's approach to corporate governance is available on the Company's website at www. vennlifesciences.com/investors/.

Enquiries:

Venn Life Sciences Holdings Plc Tel: [phone]
Cathal Friel, Chief Executive Officer

Arden Partners (Nominated Adviser and Joint Broker) Tel: [phone]
John Llewellyn-Lloyd / Ruari McGirr / Benjamin Cryer

Davy (Euronext Growth Adviser and Joint Broker) Tel: [phone]
Anthony Farrell (Corporate Finance)

Camarco (Financial PR) Tel: [phone]
Tom Huddart / Billy Clegg / Daniel Sherwen

About Venn Life Sciences

Venn Life Sciences is an Integrated Drug Development Partner offering a combination of drug development expertise and clinical trial design and management to pharmaceutical, biotechnology and medical device organisations. Venn Life Sciences has dedicated operations in France, Germany, the Netherlands, the UK and Ireland with partners across Europe and the US.

Further information in relation to Venn Life Sciences www.Vennlifesciences.com

Venn Life Sciences: [e-mail]

 

END

 

 

BOABDGDLDDDBGCU